Biotech Values

[DewDiligence]

MNTA IDIX etc: On today’s NVS CC, in reply to an analyst’s question about why NVS is using $11B of stock rather than cash to buy out ACL’s minority shareholders, CFO Raymond Breu said, “We want to maintain balance-sheet flexibility to do other smaller acquisitions.”